TY - JOUR
TI - Priorities for future research into asthma diagnostic tools: A PAN-EU
consensus exercise from the European asthma research innovation
partnership (EARIP)
AU - Garcia-Marcos, L.
AU - Edwards, J.
AU - Kennington, E.
AU - Aurora, P. and
AU - Baraldi, E.
AU - Carraro, S.
AU - Gappa, M.
AU - Louis, R. and
AU - Moreno-Galdo, A.
AU - Peroni, D. G.
AU - Pijnenburg, M.
AU - Priftis, K. N.
AU - and Sanchez-Solis, M.
AU - Schuster, A.
AU - Walker, S.
AU - EARIP
AU - Collaboration
JO - Clinical and Experimental Allergy
PY - 2018
VL - 48
TODO - 2
SP - 104-120
PB - Wiley
SN - null
TODO - 10.1111/cea.13080
TODO - null
TODO - The diagnosis of asthma is currently based on clinical history, physical
examination and lung function, and to date, there are no accurate
objective tests either to confirm the diagnosis or to discriminate
between different types of asthma. This consensus exercise reviews the
state of the art in asthma diagnosis to identify opportunities for
future investment based on the likelihood of their successful
development, potential for widespread adoption and their perceived
impact on asthma patients. Using a two-stage e-Delphi process and a
summarizing workshop, a group of European asthma experts including
health professionals, researchers, people with asthma and industry
representatives ranked the potential impact of research investment in
each technique or tool for asthma diagnosis and monitoring. After a
systematic review of the literature, 21 statements were extracted and
were subject of the two-stage Delphi process. Eleven statements were
scored 3 or more and were further discussed and ranked in a face-to-face
workshop. The three most important diagnostic/predictive tools ranked
were as follows: New biological markers of asthma (eg genomics,
proteomics and metabolomics) as a tool for diagnosis and/or monitoring,
Prediction of future asthma in preschool children with reasonable
accuracy and Tools to measure volatile organic compounds (VOCs) in
exhaled breath.
ER -